Distribution of Phase I lung cancer trials may be consolidating at top-performing US sites

medicalxpress - Between 2020 and 2024, the number of unique sites in the United States where phase I clinical trials for non-small cell lung cancer (NSCLC) were conducted decreased by 44% and became increasingly concentrated at the top 20 highest-volume clinical trial si…

AI Summary: A new analysis shows Phase I lung cancer trials are becoming concentrated at a relatively small number of leading U.S. centers, raising concerns about geographic inequity in access to early‑phase studies. The trend could speed drug development at elite sites while leaving patients in other regions with fewer experimental options and longer travel burdens.

• Conference highlights, care models and awareness (4)
• Consolidation at top U.S. Phase I centers (3)
• Early-phase trials and next-gen therapies (4)
• All Other Stories

Conference highlights, care models and awareness

Consolidation at top U.S. Phase I centers

Early-phase trials and next-gen therapies

All Other Stories